Retatrutide 10mg
Retatrutide is the latest weight loss medication that’s currently in phase 3 clinical trials. It contains the active ingredient, retatrutide, and is being developed by the same manufacturer as Mounjaro, Eli Lilly, for the management of obesity and type 2 diabetes. Retatrutide is a triple agonist, targeting the receptors of 3 hormones that can impact appetite, weight, and blood sugar levels, earning it the nicknames the “triple-G” and the “Godzilla” of weight loss jabs.
VicWide Peptides 